InvestorsHub Logo
Followers 57
Posts 5700
Boards Moderated 0
Alias Born 12/13/2004

Re: None

Tuesday, 01/04/2022 6:22:54 PM

Tuesday, January 04, 2022 6:22:54 PM

Post# of 14953
Paulsnowman keeps his eye on the ball! News expected this month!

"SP102 Fast Track. Keep Your Eyes On The Prize!

If the drug in development is designed to treat a condition where no current therapy exists, or has significant advantages over existing therapies.

Hmm, designed to treat a condition where no current therapy exists? The only non black label drug set to be approved THIS YEAR.

Significant advantages over current therapies? The only non opioid drug, that’s also well tolerated. I bet the doctors, hospitals, and insurers are going to love that.

Have you been watching the news anytime within the last year or more? People going to jail, and companies paying huge fines because of the opioid crisis. The media will eat the SP102 story up. Did I mention the only non opioid, non black label, and well tolerated drug? I did? Oops sorry, and it will have peer reviews to back it up.

The turnaround time to sales will be much faster then you think. Sales representatives in all 50 states plus territory managers already spreading the word. Sclilex can charge a high premium which Wall St will love with no competition. Estimated annual revenue is anywhere between $6-11B. Do the math X5=30-55B MC. Why do you think the Ji compensation grab?"

And I would add....that $6-11B sales is US alone. Rest of world is more than double that IMO.

"The refusal of the real is the number one dogma of our time" Rene Girard